Estudio observacional retrospectivo multicéntrico de pacientes con vejiga hiperactiva en tratamiento con mirabegrón y oxibutinina en condiciones de práctica clínica habitual / A retrospective, observational and multicentre study on patients with hyperactive bladder on treatment with mirabegron and oxybutinine under usual clinical practice conditions

Objetivo. Evaluar la persistencia terapéutica, el coste sanitario y las reacciones adversas en pacientes tratados con oxibutinina y mirabegrón para el tratamiento de la vejiga hiperactiva en condiciones de práctica médica habitual. Pacientes y métodos. Se diseñó un estudio observacional, multicéntrico, retrospectivo, realizado a partir de registros médicos de pacientes pertenecientes a 3 áreas geográficas distintas (Barcelona, Girona, Asturias). Se analizaron los 2 grupos de estudio (oxibutinina y mirabegrón). El seguimiento se realizó durante un año. La persistencia se definió como el tiempo (meses) sin abandono del tratamiento inicial o sin cambio a otra medicación al menos 60 días después de la prescripción inicial. Principales medidas: comorbilidad, uso de recursos sanitarios y reacciones adversas. Programa SPSSWIN; p<0,05. Resultados. Se analizaron 1.277 sujetos. La media de edad fue de 69,3 años y el 53,2% fueron mujeres. Por grupos: 42,9% oxibutinina y 57,1% mirabegrón. Las características demográficas y la morbilidad fueron parecidas. Los pacientes en tratamiento con oxibutinina en comparación con mirabegrón presentaron una similar persistencia al tratamiento (35,0 vs. 32,2%, p=0,294), aunque menores costes (1.151,2 vs. 1.809,6€, p<0,001). Las diferencias mayores se observaron en el precio de la medicación (279,2 vs. 692,3€, p<0,001; diferencia: −4131,€) y en las reacciones adversas (9,7 vs. 4,9%, p<0,001). Conclusiones. Los pacientes en tratamiento con oxibutinina frente a mirabegrón para la vejiga hiperactiva se asociaron a una parecida persistencia al tratamiento, menores costes sanitarios y mayores tasas de reacciones adversas de oxibutinina frente a mirabegrón

Objective. To evaluate therapeutic persistence, healthcare resources, medical costs and adverse events of oxybutynin and mirabegron treatments in patients with overactive bladder in routine medical practice. Patients and methods. An observational, retrospective, multicentre study was carried out using the records of patients attended to in 3 different geographic locations (Barcelona, Girona, Asturias). An analysis was made on the 2 study groups (oxybutynin and mirabegron). Follow-up time was one year. Persistence was defined as the time (months), without discontinuation of the initial treatment, or without change of treatment at least 60 days after the initial prescription. Primary endpoints: comorbidity, healthcare resources used, and adverse events. The data was analysed using the SPSSWIN Program, with a significance of P<.05. Results. Of the total of1,277 patients included in the study, 42.9% were on oxybutynin and 57.1% mirabegron. The mean age was 69.3 years and 53.2% were female. Demographic characteristics and morbidity were similar between the drugs and had a similar persistence (35.0% oxybutynin vs. 32.2% mirabegron, P=.294), although their costs were lower (1,151.2 vs. €1,809.6, P<.001). The biggest differences were observed in the price of medication (279.2 vs. €692.3, P<.001; a variation of: −€413.1); and adverse events (9.7 vs. 4.9%, P<.001). Conclusions. Patients treated with oxybutynin vs. mirabegron for overactive bladder had similar persistence with the treatment, lower healthcare costs, but with higher oxybutynin vs. mirabegron adverse reaction rates (AU)

[A retrospective, observational and multicentre study on patients with hyperactive bladder on treatment with mirabegron and oxybutinine under usual clinical practice conditions]. / Estudio observacional retrospectivo multicéntrico de pacientes con vejiga hiperactiva en tratamiento con mirabegrón y oxibutinina en condiciones de práctica clínica habitual.

OBJECTIVE: To evaluate therapeutic persistence, healthcare resources, medical costs and adverse events of oxybutynin and mirabegron treatments in patients with overactive bladder in routine medical practice. PATIENTS AND METHODS: An observational, retrospective, multicentre study was carried out using the records of patients attended to in 3 different geographic locations (Barcelona, Girona, Asturias). An analysis was made on the 2 study groups (oxybutynin and mirabegron). Follow-up time was one year. Persistence was defined as the time (months), without discontinuation of the initial treatment, or without change of treatment at least 60 days after the initial prescription. Primary endpoints: comorbidity, healthcare resources used, and adverse events. The data was analysed using the SPSSWIN Program, with a significance of P<.05. RESULTS: Of the total of1,277 patients included in the study, 42.9% were on oxybutynin and 57.1% mirabegron. The mean age was 69.3 years and 53.2% were female. Demographic characteristics and morbidity were similar between the drugs and had a similar persistence (35.0% oxybutynin vs. 32.2% mirabegron, P=.294), although their costs were lower (1,151.2 vs. €1,809.6, P<.001). The biggest differences were observed in the price of medication (279.2 vs. €692.3, P<.001; a variation of: -€413.1); and adverse events (9.7 vs. 4.9%, P<.001). CONCLUSIONS: Patients treated with oxybutynin vs. mirabegron for overactive bladder had similar persistence with the treatment, lower healthcare costs, but with higher oxybutynin vs. mirabegron adverse reaction rates.

Persistencia y medicación concomitante en pacientes con vejiga hiperactiva tratados con antimuscarínicos en atención primaria: estudio de base observacional / Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study

Objetivo: Evaluar la persistencia terapéutica y su relación con la medicación concomitante en pacientes tratados con fesoterodina frente a tolterodina y solifenacina para el tratamiento de la vejiga hiperactiva en condiciones de práctica médica habitual. Material y métodos: Se efectuó un diseño observacional, multicéntrico, retrospectivo, realizado a partir de registros médicos de pacientes seguidos en atención primaria. Se analizaron los 3 grupos de estudio. La persistencia se definió como el tiempo (meses), sin abandono del tratamiento inicial o sin cambio a otra medicación al menos 30 días después de la prescripción inicial. La medicación concomitante fue: antidepresivos, ansiolíticos/hipnóticos, antibióticos, antisépticos, laxantes y productos-dermatológicos. Se utilizó el programa SPSSWIN versión 17 (significación estadística: p < 0,05). Resultados: Se seleccionaron para el estudio 3.094 pacientes. La media de edad fue de 54,0 años y el 62,2% fueron mujeres. Los pacientes tratados con fesoterodina mostraron mayor persistencia al tratamiento (12 meses) en comparación con solifenacina y tolterodina (40,2% frente al 34,7% y 33,6%; p = 0,008), respectivamente. Además, también mostraron un menor uso de medicación concomitante (1,1 frente a 1,2 y 1,2 fármacos; porcentajes: 61,6% frente a 67,1% y 70,1%; p < 0,03). Conclusiones: Los pacientes en tratamiento con fesoterodina frente a solifenacina y tolterodina para la vejiga hiperactiva se asociaron a una mayor persistencia al tratamiento, con una reducción de la medicación concomitante

Objective: To assess therapeutic persistence and its relationship with concomitant medication in patients treated with fesoterodine versus tolterodine and solifenacin for overactive bladder (OAB) in standard clinical practice conditions. Material and methods: An observational, multicentre retrospective study was performed based on medical registries of patients followed-up in primary care (PC). Three study groups were analysed. Persistence was defined as the time (in months) without withdrawing from the initial therapy or without changing to another medication for at least 30 days after the initial prescription. The concomitant medications were antidepressants, anxiolytic/hypnotic agents, antibiotics, antiseptic agents, laxatives and skin products. We employed the SPSSWIN program version 17 (statistical significance, P < .05). Results: We selected 3094 patients for the study. The median age was 54.0 years and 62.2% were women. The patients treated with fesoterodine shown greater treatment persistence (12 months) when compared with those who took solifenacin and tolterodine (40.2% vs. 34.7% and 33.6%, respectively; P = .008). They also showed a lower use of concomitant medication (1.1 vs. 1.2 and 1.2 drugs, respectively; percentages: 61.6% vs. 67.1% and 70.1%, respectively; P < .03). Conclusions: The patients undergoing OAB treatment with fesoterodine, when compared with those taking solifenacin and tolterodine, were associated with greater treatment persistence and a reduced use of concomitant medication

Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study.

OBJECTIVE: To assess therapeutic persistence and its relationship with concomitant medication in patients treated with fesoterodine versus tolterodine and solifenacin for overactive bladder (OAB) in standard clinical practice conditions. MATERIAL AND METHODS: An observational, multicentre retrospective study was performed based on medical registries of patients followed-up in primary care (PC). Three study groups were analysed. Persistence was defined as the time (in months) without withdrawing from the initial therapy or without changing to another medication for at least 30 days after the initial prescription. The concomitant medications were antidepressants, anxiolytic/hypnotic agents, antibiotics, antiseptic agents, laxatives and skin products. We employed the SPSSWIN program version 17 (statistical significance, P<.05). RESULTS: We selected 3094 patients for the study. The median age was 54.0 years and 62.2% were women. The patients treated with fesoterodine shown greater treatment persistence (12 months) when compared with those who took solifenacin and tolterodine (40.2% vs. 34.7% and 33.6%, respectively; P=.008). They also showed a lower use of concomitant medication (1.1 vs. 1.2 and 1.2 drugs, respectively; percentages: 61.6% vs. 67.1% and 70.1%, respectively; P<.03). CONCLUSIONS: The patients undergoing OAB treatment with fesoterodine, when compared with those taking solifenacin and tolterodine, were associated with greater treatment persistence and a reduced use of concomitant medication.

Fractura de cadera: caracterización epidemiológica de egresos quirúrgicos, Hospital de Victoria, Chile 2009-2013 / Hip francture: epidemiological characterization of surgical discharges: Hospital of Victoria, Chile 2009-2013

INTRODUCCIÓN: La fractura de cadera (FC) es la causa más frecuente de hospitalización en servicios de urgencia ortopédicos. La mayoría ocurre en pacientes ancianos con mala calidad ósea y trauma menor. La pérdida de los reflejos protectores y reducción de la fortaleza ósea son factores de riesgo. OBJETIVO: Caracterizar epidemiológicamente los egresos quirúrgicos por FC en Hospital de Victoria 2009-2013, respecto a antecedentes nacionales, no existen registros previos, así generar información cuantitativa para decisiones administrativas. MATERIALES Y MÉTODO: Estudio cuantitativo, descriptivo y retrospectivo de corte transversal, realizado en Hospital de Victoria, Chile, durante enero-febrero 2014. Se utiliza la tabla digitalizada de Diagnósticos de Egresos Quirúrgicos entre 2009-2013. Para los criterios de inclusión, se usa la Clasificación Internacional de EnfermedadesCIE-10, seleccionando Coxartrosis, Fractura del cuello femoral, pertrocanteriana, subtrocanteriana;de los cuales los intervenidos quirúrgicamente, excluyendo los no quirúrgicos. El análisis se realizacon Microsoft Office Excel© 2007 y EPIDAT© 3,1. El estudio es aprobado por el Comité de Ética de la Universidad Mayor, Temuco, Chile. RESULTADOS: Se obtiene N= 204 con promedio de 75años, la mayoría mujeres. Del total, el 75 por ciento son fracturas del cuello femoral, y en la mayoría se usa osteosíntesis. Por otro lado, el 22 por ciento se diagnostica de coxartrosis, y todas reciben endoprótesis. DISCUSIÓN: Existe un incremento del grupo de adultos mayores como de incidencia de FC. La incidencia total a nivel países de riesgo bajo, y a nivel provinciales moderado. Determina que la patología es de mayor riesgo en Malleco respecto al nacional

INTRODUCTION: Hip fracture (HF) is the most frequent cause of hospitalization in emergency orthopedic services. They usually occur in elderly patients with poor bone quality and lower trauma. The loss of protective and reduced bone strength reflexes are risk factors. OBJECTIVE: To characterize the epidemiological profile of surgical discharges with diagnosis of HF, Hospital of Victoria, 2009-2013, regarding national background, of which there are no previous records, thus generate quantitative information for making management decisions. MATERIALS AND METHODS: a quantitative, descriptive and retrospective cross-sectional study, carried out in Hospital of Victoria, Chile, during January February 2014. It is used the digitalized Table of Diagnostics of Surgical Expenses of 2009-2013. The International Classification of Diseases ICD-10 is used for the inclusion criteria, and are selected: Coxarthrosis, Fracture of the femoral neck, pertrochanteric, and subtrochanteric; of which only surgically. Excluding non-surgical. The analysis is performed with Microsoft Office Excel 2007 and EPIDAT © © 3.1. The study is approved by the Ethics Committee of the Universidad Mayor, Temuco, Chile. RESULTS: N= 204 is obtained, mostly women, mean 75.5 years. Of the total, 75.5 percent are femoral neck fractures, of which67.5 percent is used osteosynthesis. Furthermore, 22.1 percent were diagnosed with coxarthrosis, and all of them receiving endoprosthesis. DISCUSSION: There is a constant increase in the elderly group and incidence of HF. The national overall incidence was set as low risk, but atlocal level, it is moderate. It determines that the condition is riskier in the Province of Malleco rather than the national level

Uso de recursos sanitarios y costes asociados en pacientes ancianos vulnerables no institucionalizados con vejiga hiperactiva tratados con antimuscarínicos en la práctica médica habitual / Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice

Objetivo: Evaluar el uso de recursos y costes sanitarios en pacientes ancianos vulnerables no institucionalizados con vejiga hiperactiva (VH) tratados con fesoterodina, solifenacina o tolterodina en la práctica médica habitual. Material y métodos: Estudio multicéntrico, retrospectivo, realizado a partir de los registros de pacientes atendidos durante 2008-2010 en 3 localidades geográficas y que iniciaron tratamiento con antimuscarínicos (fesoterodina, solifenacina y tolterodina) para la VH. El atributo de vulnerabilidad se basó en reunir, al menos, 3 de los criterios del Vulnerable-Elders Survey-13; edad > 75 años, salud pobre/normal para la edad y alguna dificultad en al menos una actividad física diaria. Principales medidas: comorbilidad, persistencia y uso de recursos y costes. El seguimiento de los pacientes se realizó durante 52 semanas. Se utilizó un modelo lineal general con covariables y remuestreo (1.000) aleatorio para construir el IC 95% de las diferencias de costes entre fármacos. Resultados: Se analizaron registros de 552 pacientes (50,8% mujeres, edad media: 80,2 años), tratados con fesoterodina (n = 58), solifenacina (n = 252) o tolterodina (n = 212). El uso de absorbentes fue del 20,7, 29,4 y 33,0% (p = 0,186), respectivamente. La persistencia al tratamiento fue ligeramente mayor con fesoterodina. Los costes sanitarios paciente/año fueron inferiores con fesoterodina, 1.775 euros (1.550-2.014) vs. solifenacina 2.062 euros (1.911-2.223) y tolterodina 2.149 euros (1.978-2.307), p = 0,042, como consecuencia de una menor utilización de visitas y medicación concomitante. Conclusiones: A pesar de las posibles limitaciones del estudio, los pacientes ancianos vulnerables no institucionalizados con VH tratados con fesoterodina, en comparación con solifenacina o tolterodina, se asociaron a una menor utilización de recursos y costes sanitarios

Objective: To evaluate the use of resources and health costs in vulnerable elderly institutionalized patients with overactive bladder (OAB) treated with fesoterodine, tolterodine or solifenacin in routine medical practice. Material and methods: A multicenter retrospective study, from the records of patients treated during 2008-2010 in three geographical locations and starting treatment with antimuscarinic (fesoterodine, solifenacin and tolterodine) for OAB. The attribute of vulnerability was based on collecting at least 3 of the Vulnerable Elders Survey criteria-13, age > 75 years, poor/average age for health and difficulty in at least one daily physical activity. Main measures: morbidity, persistence and resource use and costs. Monitoring of patients was conducted over 52 weeks. A general linear model with covariates and bootstraping (1000) at random was used to construct the 95% CI of the cost differences between drugs. Results: Records of 552 patients (50.8% women, mean age: 80.2 years) were analyzed. Treated with fesoterodine (N = 58), solifenacin (N = 252) or tolterodine (N = 212). The use of absorbent was 20.7%, 29.4% and 33.0% (p = 0.186), respectively. Persistence to treatment was slightly greater with fesoterodine. The patient healthcare costs/year were lower with fesoterodine, euros 1775 (1550-2014) vs. solifenacin euros 2062 (1911-2223) and tolterodine euros 2149 (1978-2307), p = 0.042, as a result of lower utilization visits and concomitant medication. Conclusions: Despite the potential limitations of the study, the vulnerable elderly non institutionalized patients with OAB treated with fesoterodine, compared to solifenacin or tolterodine were associated with lower resource utilization and healthcare costs

Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.

OBJECTIVE: To evaluate the use of resources and health costs in vulnerable elderly institutionalized patients with overactive bladder (OAB) treated with fesoterodine, tolterodine or solifenacin in routine medical practice. MATERIAL AND METHODS: A multicenter retrospective study, from the records of patients treated during 2008-2010 in three geographical locations and starting treatment with antimuscarinic (fesoterodine, solifenacin and tolterodine) for OAB. The attribute of vulnerability was based on collecting at least 3 of the Vulnerable Elders Survey criteria-13, age>75 years, poor/average age for health and difficulty in at least one daily physical activity. MAIN MEASURES: morbidity, persistence and resource use and costs. Monitoring of patients was conducted over 52 weeks. A general linear model with covariates and bootstraping (1000) at random was used to construct the 95% CI of the cost differences between drugs. RESULTS: Records of 552 patients (50.8% women, mean age: 80.2 years) were analyzed. Treated with fesoterodine (N=58), solifenacin (N=252) or tolterodine (N=212). The use of absorbent was 20.7%, 29.4% and 33.0% (P=.186), respectively. Persistence to treatment was slightly greater with fesoterodine. The patient healthcare costs/year were lower with fesoterodine, €1,775 (1550-2014) vs. solifenacin €2,062 (1911-2223) and tolterodine €2,149 (1,978-2,307), P=.042, as a result of lower utilization visits and concomitant medication. CONCLUSIONS: Despite the potential limitations of the study, the vulnerable elderly non institutionalized patients with OAB treated with fesoterodine, compared to solifenacin or tolterodine were associated with lower resource utilization and healthcare costs.

Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis.

BACKGROUND: Although incrimination of the intestinal microbiota in the pathogenesis of IBD is widely accepted, few data are available about the role of specific bacteria. Potentially, Faecalibacterium prausnitzii, bacteria with anti-inflammatory properties, might be deficient in ulcerative colitis (UC). AIM: To quantify F. prausnitzii in the faecal microbiota of UC patients in remission and determine its relationship with relapse. METHODS: A cross-sectional study included 116 UC patients in remission, 29 first-degree relatives and 31 healthy controls. A subset of eighteen patients, recruited during the first month of remission, underwent a 1-year follow-up. Total bacteria and F. prausnitzii were measured by quantitative Real Time PCR (qPCR, copies/g). Calprotectin was determined as inflammatory index (µg/g). RESULTS: We found that F. prausnitzii was reduced in patients (median, IQR: 1.4 × 108 , 5.1 × 107-4.5 × 108) and relatives (1.7 × 108, 9.3 × 107-5.1 × 108) vs. controls (6.5 × 108, 3.7 × 108-1.6 × 109, P < 0.0001). Moreover, low counts of F. prausnitzii were associated with less than 12 months of remission (8.0 × 107, 2.0 × 107-3.5 × 108 vs. 2.1 × 108, 1.0 × 108-7.9 × 108, P < 0.001) and more than 1 relapse/year (8.0 × 107, 3.2 × 107-3.8 × 108 vs. 1.9 × 108, 6.8 × 107-6.0 × 108, P < 0.01). When patients were followed up, F. prausnitzii increased steadily until reaching similar levels to those of controls if remission persisted (2.9 × 108, 9.3 × 106-1.2 × 109; calprotectin: 76, 19-212), whereas it remained low if patients relapsed (2.2 × 108, 1.4 × 106-3.3 × 108; calprotectin: 1760, 844-3662 P < 0.05 vs. controls). CONCLUSIONS: Defective gut colonisation by F. prausnitzii occurred in UC patients during remission and in their unaffected relatives. The recovery of the F. prausnitzii population after relapse is associated with maintenance of clinical remission.

Morbilidad y coste asociado a los trastornos neurológicos / Morbidity and costs associated with neurological disorders

No disponible

Factores pronósticos de fracaso terapéutico al radioyodo en enfermedad de Graves / Frequency and prognostic factors of radioiodine treatment failure in basedow Graves disease

Background: Radioiodine treatment fails in 17 percent of patients with Basedow Graves disease (BGD). Aim: To assess the frequency and possible associated factors of treatment failure of the first radioiodine dose in patients with BGD. Material and Methods: Review of medical records of patients with BGD treated with radioiodine at a general hospital between 2004 and 2008. Normal thyroid function or hypothyroidism ensuing after treatment were considered as treatment success criteria. Results: According to the databases of the hospital, 298 patients received radioiodine in the study period. Of these, 254 medical records were recovered and 86 were analyzed. Treatment success and failure was recorded in 67 (78 percent) and 19 (22 percent) patients, respectively. The mean dose used was 12 +/- 2 mCi. Clinically determined goiter size and a high free thyroxin level were significantly associated to treatment failure. The area under the receiver operating characteristic curve (ROC) for a thyroid weight over 60 g, estimated clinically was 0.73, rendering a sensitivity and specificity of 63 and 89 percent respectively, for this parameter as predictor or treatment failure. Conclusions: Thyroid gland size may be a predictor of radioiodine treatment failure. However the variability of the clinical estimation of this parameter casts doubts about its usefulness.

Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life.

UNLABELLED: One of the objectives in the treatment of the inflammatory bowel disease (IBD) is improving the patient's quality of life. However, we do not dispose of validated criteria to determine the questionnaire's scoring threshold that has to be reached in order to be able to assert that the patients' quality of life has normalized. OBJECTIVE: To determine the normality punctuation cutoff in the IBD specific quality of life questionnaire IBDQ-36. METHOD: Cross-sectional study in a random sample of IBD patients, who have completed the questionnaires IBDQ-36 and EuroQol-5D. The IBDQ-36 normality was calculated according to its equivalence with the EuroQol-5D tariff ≥ 0.90, which corresponds to the 95% CI of the average obtained in a Spanish general population. RESULTS: 218 patients were included. According to the EuroQol-5D tariff, 70 patients were considered to have a normal quality of life and 148 a quality of life poorer than the general population. The IBDQ-36 scoring was significantly higher in the normal quality of life group (222.9 ± 22.8 vs. 171.4 ± 44.8 in the bad quality of life group, p<0.001). According to the linear regression between IBDQ-36 and EuroQol-5D, the cutoff point is 209, with a sensitivity and specificity to predict normality of 0.74 and 0.71 respectively. CONCLUSIONS: Scores of the IBDQ-36 equal or superior to 209 suggest quality of life comparable to that perceived by the general population. This study allowed to set a threshold of normality in the management of the inflammatory bowel diseases.

Influence of colectomy on hydrogen excretion in breath.

INTRODUCTION: Hydrogen breath test is the most commonly used method to analyze carbohydrate absorption and diagnose carbohydrate malabsorption. The result of the H(2) breath test is influenced by different factors, which are mostly related to quantitative or qualitative aspects of colonic flora. A scarcely studied variable is the effect of colonic anatomical integrity on H(2) excretion in breath. PURPOSE: The present study aims to determine whether loss of colonic integrity reduces H(2) excretion capacity after an oral load of an unabsorbable carbohydrate. METHODS: An observational study was conducted in three patient groups: controls with preserved colon, patients with partial colectomy, and patients with complete colectomy and ileostomy. H(2) concentration in breath was measured by gas chromatography every 10 min for 3 h after oral lactulose administration. RESULTS: Twenty-two patients with partial colectomy, 18 controls with preserved colon, and seven patients with ileostomy were included. H(2) excretion after lactulose did not differ between patients with partial colectomy and controls (basal excretion = 8.5 vs 4 ppm; delta increase = 50.0 vs 47.5 ppm; area under the curve = 4,480.0 vs 4,710.5 ppm/min). In contrast, H(2) excretion was significantly lower in the ileostomy group. CONCLUSIONS: Partial colectomy does not influence the capacity for H(2) excretion after oral unabsorbable carbohydrate administration.

Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin.

BACKGROUND: Inulin and oligofructose promote selective growth of saccharolytic bacteria with low inflammatory potential. OBJECTIVE: To test the effect of oligofructose-enriched inulin in patients with active ulcerative colitis. DESIGN: Prospective, randomized, placebo controlled pilot trial. Eligible patients had been previously in remission with mesalazine as maintenance therapy or no drug, and presented with a relapse of mild to moderate activity. They were treated with mesalazine (3 g/day) and randomly allocated to receive either oligofructose-enriched inulin (12 g/day, p.o., n = 10) or placebo (12 g/day of maltodextrin, p.o., n = 9) for 2 week. Primary endpoint was the anti-inflammatory effect as determined by reduction of calprotectin and human DNA in faeces. RESULTS: Rachmilewitz score decreased in both groups, reaching statistical significance at day 14 (P < 0.05). Oligofructose-enriched inulin was well-tolerated and dyspeptic symptoms scale decreased significantly with active treatment but not with placebo. At day 7, an early significant reduction of calprotectin was observed in the group receiving oligofructose-enriched inulin (day 0: 4377 +/- 659 microg/g; day 7: 1033 +/- 393 microg/g, P < 0.05) but not in the placebo group (day 0: 5834 +/- 1563 microg/g; day 7: 4084 +/- 1395 microg/g, n.s.). Changes in faecal concentration of human DNA were not significant. CONCLUSION: In active ulcerative colitis, dietary supplementation with oligofructose-enriched inulin is well tolerated and is associated with early reduction in faecal calprotectin.

[Family practice and diagnosis of cancer]. / El médico de atención primaria y el diagnóstico de los pacientes con cáncer.

OBJECTIVES: To describe the types of cancer identified in primary health care, their clinical presentation, management until diagnosis and delay in diagnosis. DESIGN: Descriptive study based on secondary information from medical records. SETTING: Two urban health care centres in Mallorca, Spain. PARTICIPANTS: Patients over 14 years old diagnosed with cancer between 1994 and 1998. MEASUREMENTS: Age, sex, location of tumour, symptoms, role of family doctor, specialist referral, care environment, time from first symptom to diagnosis, and stage of tumour. RESULTS: We identified 408 cancers. Mean age at diagnosis was 66.5 years (95% CI, 65.3-67.7); 237 (58.1%) were male. The most frequent tumours were colorectal, lung, prostate, breast and bladder, and the most common symptom was pain (33.1%; 95% CI, 28-38.3). The family doctor was involved in 63% of diagnoses (95% CI, 58.2-67.8). Mean delay from first symptom until diagnosis was 90 days, of which 26 were attributed to the patient and 55 to primary health care services. For colorectal, lung and prostate cancers, delay was shorter. The tumour was less advanced at diagnosis when family doctors were involved. CONCLUSIONS: Family doctors are involved in the diagnosis of most cancers. In colorectal, lung and prostate cancers, their contribution could improve prognosis. More studies are needed to confirm these findings.

El médico de atención primaria y el diagnóstico de los pacientes con cáncer / Family practice and diagnosis of cancer

Objetivos. Describir los tipos de cáncer identificados en atención primaria, su forma de presentación clínica, el proceso asistencial seguido hasta su diagnóstico y los tiempos de demora diagnóstica. Diseño. Estudio descriptivo basado en la recogida de información secundaria a partir de la historia clínica. Emplazamiento. Dos centros de salud urbanos de Mallorca. Participantes. Cánceres diagnosticados, entre 1994 y 1998, en usuarios mayores de 14 años. Mediciones. Edad, sexo, localización, desencadenantes, intervención del médico de familia, tipo de derivación, ámbito de actuación, intervalos de tiempo desde el inicio de síntomas hasta el diagnóstico y estadio. Resultados. Se identificaron 408 cánceres. La media de edad en el momento del diagnóstico fue de 66,5 años (intervalo de confianza [IC] del 95%, 65,3-67,7), 237 (58,1%) en varones. Los más frecuentes fueron colorrectal, pulmón, próstata, mama y vejiga. El síntoma más frecuente fue el dolor, que se presenta en el 33,1% (IC del 95%, 28-38,3). El médico de familia intervino en el 63,0% (IC del 95%, 58,2-7,8). La demora total fue de 90 días de mediana, mientras que en atención primaria fue de 55 días y la debida al paciente de 26 días. En los casos en que intervino el médico de familia, la demora fue menor y se llegó al diagnóstico en estadios más precoces para el cáncer colorrectal, de pulmón y de próstata, pero no en el resto de las localizaciones. Conclusiones. El médico de AP interviene en el diagnóstico de la mayoría de los cánceres. Su intervención podría mejorar el pronóstico en el cáncer colorrectal, de pulmón y de próstata. Deben realizarse estudios que confirmen estos hallazgos

Objectives. To describe the types of cancer identified in primary health care, their clinical presentation, management until diagnosis and delay in diagnosis. Design. Descriptive study based on secondary information from medical records. Setting. Two urban health care centres in Mallorca, Spain. Participants. Patients over 14 years old diagnosed with cancer between 1994 and 1998. Measurements. Age, sex, location of tumour, symptoms, role of family doctor, specialist referral, care environment, time from first symptom to diagnosis, and stage of tumour. Results. We identified 408 cancers. Mean age at diagnosis was 66.5 years (95% CI, 65.3-67.7); 237 (58.1%) were male. The most frequent tumours were colorectal, lung, prostate, breast and bladder, and the most common symptom was pain (33.1%; 95% CI, 28-38.3). The family doctor was involved in 63% of diagnoses (95% CI, 58.2-67.8). Mean delay from first symptom until diagnosis was 90 days, of which 26 were attributed to the patient and 55 to primary health care services. For colorectal, lung and prostate cancers, delay was shorter. The tumour was less advanced at diagnosis when family doctors were involved. Conclusions. Family doctors are involved in the diagnosis of most cancers. In colorectal, lung and prostate cancers, their contribution could improve prognosis. More studies are needed to confirm these findings

[Prospective study of prevalence and risk factors for painful phantom limb in the immediate postoperative period of patients undergoing amputation for chronic arterial ischemia]. / Estudio prospectivo de la prevalencia y factores de riesgo de miembro fantasma doloroso en el postoperatorio inmediato de pacientes sometidos a amputación por isquemia arterial crónica.

OBJECTIVE: To determine the prevalence and risk factors associated with postoperative phantom limb pain (PLP) in patients amputated for chronic ischemia of a lower limb. PATIENTS AND METHOD: Prospective, longitudinal, epidemiological study of patients amputated for chronic grade IV ischemia. PLP, defined as the perception of pain > or = 3 on a verbal scale of 0 to 10, was assessed in the first week after surgery. Candidate risk factors analyzed were patient characteristics, course of ischemic disease, and features of surgery or anesthetic technique. RESULTS: The prevalence of PLP was 26% (14 patients) in a total of 53 amputations performed on the same number of patients over one year. Mean patient age was 68.4 +/- 11.2 years, and 45 (84.9%) were diabetics. Phantom limbs were felt by 9 patients (17%), and a painful stump was reported by 5 (10%). The most common PLP symptoms were a burning sensation and painful paresthesia. Risk factors identified, in order of statistical significance, were prior amputation (p < 0.0002), oral antidiabetic therapy (p < 0.02) and type of amputation (p = 0.05). Logistic regression analysis of variables revealed increased risk of PLP in patients with a prior amputation (odds ratio [OR] 8.1) and those receiving oral antidiabetic therapy (OR 3.9). Insulin treatment was a protective factor (OR 0.5). CONCLUSIONS: The prevalence of PLP among patients with chronic ischemia of the lower limb in our setting is considerable, although low in comparison to the prevalence reported for other settings. Identifying risk factors such as those described in this study helps to establish the profile of patients toward whom to direct measures to prevent PLP.

Estudio prospectivo de la prevalencia y factores de riesgo de miembro fantasma doloroso en el postoperatorio inmediato de pacientes sometidos a amputación por isquemia arterial crónica / Prospective study of the prevalence and risk factors of early postoperative phantom limb pain after amputation for chronic arterial ischemia

Objetivo: Determinar la prevalencia y los factores de riesgo asociados a la presentación de miembro fantasma doloroso (MFD) postoperatorio en pacientes amputados por isquemia crónica del miembro inferior. Pacientes y método: Estudio epidemiológico, longitudinal y prospectivo en pacientes amputados por isquemia crónica grado IV. Evaluados en la primera semana del postoperatorio, definimos MFD como la percepción dolorosa (dolor 3, en una escala verbal de 0 a 10). Los posibles factores de riesgo los agrupamos en torno a las características de los pacientes, evolución de la propia enfermedad isquémica y las relativas a la intervención y la anestesia. Resultados: En un total de 53 amputaciones realizadas en un año sobre un número equivalente de pacientes con una edad media de 68,4ñ11,2 años, de los cuales 45 (84,9 por ciento) eran diabéticos, determinamos una prevalencia de MFD del 26 por ciento (14 pacientes). Miembro fantasma se presentó en 9 (17 por ciento), mientras que muñón doloroso se observó en 5 (10 por ciento). Las formas más frecuentes de presentación del MFD fueron el dolor quemante y las parestesias dolorosas. Los factores de riesgo identificados en orden de potencia estadística fueron: las amputaciones previas (p < 0,0002), el tratamiento con antidiabéticos orales (p < 0,02) y el tipo de amputación (p = 0,05). El estudio multivariable mediante regresión logística determinó un incremento del riesgo relativo de MFD en pacientes con amputación previa [odds ratio (OR)] de 8,1 veces y de 3,9 para los que recibían tratamiento con antidiabéticos orales. El tratamiento con insulina se reveló como un factor protector (OR: 0,5). Conclusiones: La prevalencia en nuestro medio del MFD en pacientes con isquemia crónica de extremidades inferiores, aun siendo baja en relación con otras situaciones clínicas, no es nada despreciable. La identificación de factores de riesgo, como los descritos, nos permite establecer el perfil del paciente hacia quien dirigir los mayores esfuerzos preventivos de esta complicación. (AU)

[Locoregional anesthesia for cesarean section in full-term pregnancy with single ventricle]. / Anestesia locorregional para cesárea en gestante a término con la presencia de un ventrículo único.

A parturient at full-term diagnosed of a single ventricle and with the fetus in podalic presentation underwent scheduled delivery by cesarean section under epidural anesthesia without complications. The number of women with this cyanogenic congenital heart disease who reach childbearing age is high. The rate of death among parturients with mild or moderate heart disease is low; however, mortality is higher for high-risk women for whom conception is considered contraindicated due to heart disease. Few cases of single-ventricle congenital heart disease have been reported in the literature.

Anestesia locorregional para cesárea en gestante a término con la presencia de un ventrículo único / Locoregional anesthesia for full-term cesarean delivery of a parturient with a single ventricle

Una gestante a término de 29 años, diagnosticada de ventrículo único y con un feto con presentación podálica, motivo por el que se indicó el final del embarazo mediante intervención cesárea, fue intervenida bajo anestesia epidural sin complicaciones.El número de mujeres con enfermedad cardíaca congénita cianógena que llegan a la edad de procrear es cada día mayor. Las gestantes con cardiopatías leves o moderadas presentan una mortalidad materna baja. Sin embargo, la mortalidad se incrementa en aquellas gestantes valoradas de alto riesgo, considerándose la cardiopatía una contraindicación para la concepción. Hay pocas experiencias recogidas en gestantes cuya cardiopatía congénita consiste en la existencia de un único ventrículo (AU)

No disponible